Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong Wook Kim, Jerald Radich, Michael Savona, Patricia Martin-Regueira, Oumar Sy, Renuka Gurnani, Giuseppe Saglio

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Fingerprint

Dive into the research topics of 'Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study'. Together they form a unique fingerprint.

Medicine & Life Sciences